fludarabine has been researched along with B-Cell Lymphoma in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (13.33) | 18.2507 |
| 2000's | 17 (37.78) | 29.6817 |
| 2010's | 21 (46.67) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| de Castro, DG; Dietrich, S; Dreger, P; Dreyling, M; Grabe, N; Hermine, O; Hoster, E; Hüttl, K; Klapper, W; Kluin-Nelemans, HC; Müller-Tidow, C; Ott, G; Pott, C; Roider, T; Rosenwald, A; Stewart, JP; Wang, X | 1 |
| Alani, M; Baugier de Materre, A; Besançon, A; Denizon, N; Farhi, J; Ghnaya, H; Laribi, K | 1 |
| Blumenthal, GM; Bouchkouj, N; Bryan, W; de Claro, RA; George, B; Kasamon, YL; Lee, S; Lin, X; McKee, AE; Pazdur, R | 1 |
| Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Maloney, DG; Press, OW; Puronen, CE; Sandmaier, BM; Stevenson, PA; Storb, RF | 1 |
| Alonso Caballero, C; Barrenetxea Lekue, C; D'Amore, F; Grasso Cicala, S; Herráez Rodríguez, S; Jørgensen, JM; Leal Martínez, I; Leppä, S; Stauffer Larsen, T; Toldbod, H | 1 |
| Barker, JN; Castro-Malaspina, H; Ceberio, I; Devlin, SM; Giralt, S; Goldberg, JD; Jakubowski, AA; Koehne, G; Lechner, L; Moskowitz, CH; Papadopoulos, EB; Perales, MA; Sauter, CS; Zelenetz, AD; Zheng, J | 1 |
| Appelbaum, FR; Cassaday, RD; Fisher, DR; Gooley, TA; Gopal, AK; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Shields, A | 1 |
| Carpenter, RO; Chen, CC; Dudley, ME; Feldman, S; Feldman, T; Goy, A; Hughes, MS; Kassim, SH; Kochenderfer, JN; Kranick, SM; Li, YF; Lu, L; Morton, KE; Nath, A; Nathan, DA; Ngo, LT; Phan, GQ; Raffeld, M; Rosenberg, SA; Sherry, RM; Somerville, RP; Spaner, DE; Stetler-Stevenson, M; Toomey, MA; Wang, ML; Yang, JC | 1 |
| Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S | 1 |
| Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Guthrie, KA; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Rezvani, AR; Sandmaier, BM; Sorror, ML; Storb, RF; Storer, BE | 1 |
| Hasegawa, K; Hirayama, Y; Ishihara, T; Kanagawa, M; Koyama, J; Suzuki, T; Terui, T | 1 |
| Thieblemont, C | 1 |
| Ando, K; Hayashi, M; Hotta, T; Ishizawa, K; Itoh, K; Matsusako, M; Morishima, Y; Nakata, M; Nawano, S; Ogura, M; Taniwaki, M; Terauchi, T; Tobinai, K; Uchida, T; Watanabe, T; Yamamoto, J | 1 |
| Baiocchi, RA; Blum, KA; Byrd, JC; Fischer, DB; Grever, MR; Johnson, AJ; Kraut, EH; Lin, TS; Mitchell, SM; Moran, ME; Porcu, P; Ruppert, AS; Schaaf, LJ | 1 |
| Baldini, L; Federico, M; Ferrario, A; Goldaniga, MC; Luminari, S; Mannina, D; Marcheselli, L; Mazza, P; Merli, F; Russo, M; Stelitano, C | 1 |
| Lech-Maranda, E; Robak, P; Robak, T | 1 |
| Che, Y; Christopherson, RI; Henrich, S; Kohnke, PL; Mactier, S | 1 |
| Gopal, AK; Guthrie, KA; Maloney, DG; Matesan, MC; Oliveira, G; Pagel, JM; Press, OW; Rajendran, J; Storb, RF | 1 |
| Bahlis, NJ; Carlson, L; Duan, Q; Duggan, P; Hasegawa, W; Russell, JA; Stewart, DA; Voralia, M | 1 |
| Sinsabaugh, C | 1 |
| Baldini, L; Ferrario, A; Gamba, E; Goldaniga, M; Mannina, D; Merli, F; Musto, P; Olivero, B; Pulsoni, A; Rigacci, L; Rossi, F; Rossi, G; Stelitano, C; Tedeschi, A; Vitolo, U | 1 |
| Chen, CH; Kuo, CY; Ma, MC; Pei, SN; Rau, KM; Su, CY; Wang, MC | 1 |
| Ba, Y; Hou, Y; Wang, HQ | 1 |
| Arima, H; Imai, Y; Inoue, D; Kiuchi, M; Maruoka, H; Matsushita, A; Mori, M; Nagano, S; Oita, T; Tabata, S; Takahashi, T; Takiuchi, Y; Yamashiro, A | 1 |
| Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Improta, S; Mastrullo, L; Nitrato Izzo, G; Polistina, MT; Quirino, AA; Rocco, S; Russolillo, S; Sagristani, M | 1 |
| Borelli, S; Herr, D; Kempf, W; Trojan, A | 1 |
| Au, WY; Chan, LC; Kwong, YL; Liang, R | 1 |
| Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M | 1 |
| Audouin, J; Compérat, E; Delmer, A; Diebold, J; Le Tourneau, A; Molina, TJ | 1 |
| Bonnefoy-Bérard, N; Brien, G; Trescol-Biemont, MC | 1 |
| Cassells, R; Cheow, HK; Giles, A; Lim, Z; Mir, N | 1 |
| Feldman, EJ; Keating, MJ | 1 |
| Piro, LD; Saven, A | 1 |
| Abbondanzo, SL; Aguilera, NI; Byrd, JC; Diehl, LF; Lichy, JH; Shields, DJ | 1 |
| Brugiatelli, M; Callea, I; Callea, V; Console, G; Dattola, A; di Raimondo, F; Iacopino, P; Morabito, F; Pucci, G; Stelitano, C | 1 |
| Christopherson, RI; Mulligan, SP; Szabados, E; Wilson, PK | 1 |
| Hieke, K; Howard, P; Kerrigan, M; McIntyre, AM; Smartt, PF; Sweetenham, J; Townshend, S | 1 |
| Belanger, C; François, S; Hermine, O; Lebas de La Cour, JC; Lefrère, F; Tilly, H; Troussard, X; Valensi, F; Varet, B | 1 |
| Catovsky, D; Dearden, CE; Matutes, E | 1 |
| Foss, FM | 1 |
| Aul, C; Gattermann, N; Germing, U; Misgeld, E | 1 |
| Benyunes, M; Bernstein, SH; Bernstein, ZP; Brown, K; Czuczman, MS; Fallon, A; Grillo-López, AJ; Klippenstein, D; Loud, P; McCarthy, P; Miller, K; Mohr, A; Rock, MK; Skipper, M; Stewart, C; Wentling, D | 1 |
| Abruzzo, LV; Jones, D; Keating, MJ; Luthra, R; Manning, JT; Medeiros, LJ; Rosales, CM; Vega, F | 1 |
| Brugger, S; Gisslinger, H; Greinix, HT; Kalhs, P; Keil, F; Lechner, K; Mannhalter, C; Mitterbauer, G; Mitterbauer, M; Moser, K; Prinz, E | 1 |
8 review(s) available for fludarabine and B-Cell Lymphoma
| Article | Year |
|---|---|
Pixantrone beyond monotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, B-Cell; Mitoxantrone; Prednisone; Rituximab; Salvage Therapy; Vidarabine; Vincristine | 2019 |
Non-MALT marginal zone lymphomas.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Italy; L-Lactate Dehydrogenase; Lymph Nodes; Lymphocytosis; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prognosis; Splenectomy; Splenic Neoplasms; Survival Analysis; Vidarabine | 2008 |
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Mice; Rituximab; Vidarabine | 2010 |
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bleomycin; Bone Marrow; Bone Marrow Diseases; Chemotherapy, Adjuvant; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Paraproteins; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Fludarabine in the treatment of lymphoproliferative malignancies.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Vidarabine | 1993 |
2-Chlorodeoxyadenosine treatment of lymphoma.
Topics: Adenosine Deaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Pentostatin; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
Combination therapy with purine nucleoside analogs.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxyadenosines; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferons; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Pentostatin; Purine Nucleosides; Treatment Outcome; Vidarabine | 2000 |
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vidarabine; Vincristine | 2002 |
13 trial(s) available for fludarabine and B-Cell Lymphoma
| Article | Year |
|---|---|
The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Oxaliplatin; Prednisone; Primary Cell Culture; Rituximab; SAM Domain and HD Domain-Containing Protein 1; Tissue Array Analysis; Vidarabine; Vincristine | 2021 |
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy; Cyclophosphamide; Drug Approval; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Leukapheresis; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine; Young Adult | 2019 |
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prospective Studies; Rituximab; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2014 |
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Radioimmunotherapy; Radiopharmaceuticals; Transplantation, Autologous; Vidarabine | 2014 |
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Immunotherapy, Adoptive; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Receptors, Antigen, T-Cell; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Yttrium Radioisotopes | 2015 |
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Rituximab; Vidarabine | 2010 |
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Italy; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine; Young Adult | 2011 |
⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Humans; Lymphoma, B-Cell; Middle Aged; Radioimmunotherapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2011 |
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2012 |
24 other study(ies) available for fludarabine and B-Cell Lymphoma
| Article | Year |
|---|---|
Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; France; Humans; Immunosuppression Therapy; Incidence; Lymphoma, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Rituximab; Survival Rate; Vidarabine | 2018 |
Long-Term Follow-Up of
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2018 |
B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lymphoma, B-Cell; Prednisone; Recurrence; Remission Induction; Risk; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Virus Activation | 2014 |
Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cladribine; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Humans; Lymphoma, B-Cell; Mitochondria; Molecular Chaperones; Proteome; Purines; Vidarabine | 2011 |
Atypical cytogenetics in therapy-related myelodysplastic syndrome secondary to indolent B-cell lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 20; Female; Flow Cytometry; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2011 |
Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Serologic Tests; Titrimetry; Vidarabine; Vincristine; Virus Activation | 2012 |
Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisolone; Rituximab; Teniposide; Vidarabine | 2012 |
Successful treatment of γ-heavy-chain disease with rituximab and fludarabine.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Heavy Chain Disease; Humans; Lymphoma, B-Cell; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Severe T-mediated bone marrow aplasia in a patient with splenic lymphoma with villous lymphocytes (SLVL) previously treated with fludarabine regimen.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Humans; Lymphoma, B-Cell; Splenic Neoplasms; T-Lymphocytes; Vidarabine | 2004 |
Fludarabine: risk factor for aggressive behaviour of squamous cell carcinoma of the skin?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Lymphoma, B-Cell; Male; Skin Neoplasms; T-Lymphocytes; Vidarabine | 2005 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine | 2006 |
Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus- positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Humans; Immunoglobulin A; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Tumor Lysis Syndrome; Vidarabine | 2006 |
Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Caspases; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; Minor Histocompatibility Antigens; Proto-Oncogene Proteins c-bcl-2; Rituximab; RNA, Small Interfering; Tumor Cells, Cultured; Vidarabine; Vincristine | 2007 |
Diffuse large B-cell lymphoma developing following treatment of Waldenstrom's macroglobulinaemia: spontaneous resolution upon cessation of fludarabine.
Topics: Aged; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2007 |
Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Viral; Antineoplastic Agents; CD4 Lymphocyte Count; Cell Transformation, Neoplastic; DNA Primers; Female; Herpesvirus 4, Human; Humans; In Situ Hybridization; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Vidarabine; Viral Matrix Proteins | 1997 |
In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Lymphoma, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines.
Topics: Adenosine Deaminase Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Division; Cladribine; Deoxyribonucleotides; Enzyme Inhibitors; Humans; Kinetics; Leukemia, T-Cell; Lymphoma, B-Cell; Pentostatin; Ribonucleotides; Tumor Cells, Cultured; Vidarabine | 1998 |
Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
Topics: Ambulatory Care; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cyclophosphamide; Doxorubicin; Humans; Length of Stay; Lymphoma, B-Cell; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Rituximab; Vidarabine; Vincristine | 1999 |
Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Vidarabine | 2000 |
Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Pentostatin; Sezary Syndrome; Survival Rate; Vidarabine | 2000 |
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2001 |
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
Topics: Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Ribosomal Proteins; RNA-Binding Proteins; Vidarabine | 2002 |
Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Lymphoma, B-Cell; Middle Aged; Multiple Myeloma; Remission Induction; Reoperation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2002 |